A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies.

Trial Profile

A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2014

At a glance

  • Drugs FT 1050 (Primary) ; Antithymocyte globulin; Fludarabine; Melphalan; Sirolimus; Tacrolimus
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Fate Therapeutics
  • Most Recent Events

    • 08 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top